Background
T2D
SECONDARY, TYPE 2 DIABETES
Edited by: Qi Pan, Peking University, ChinaReviewed by: Guiju Sun, Southeast University, China; Vahidreza Ostadmohammadi, Kashan University of Medical Sciences, Iran; Emanuel L. Peter, National Institute of Medical Research, Tanzania†These authors have contributed equally to this work and share first authorshipPrevious studies found that Jinlida granules could significantly reduce blood glucose levels and enhance the low-glucose action of metformin. However, the role of Jinlida in the standard-reaching rate of blood glucose and improving clinical symptoms has yet to be studied. We aimed to elaborate on the efficacy of Jinlida in type 2 diabetes (T2D) patients who experience clinical symptoms based on secondary analysis of a randomized controlled trial.